Convergence Quantum II Series

Our goal is to bring together the life sciences leaders and quantum innovators in a series of curated gatherings that will define and direct the next steps in applied quantum computing to shorten drug discovery and development timelines.

CONVERGENCE QUANTUM II
March 24, 2026
The Engine | Cambridge MA

The second edition of Convergence Quantum gathered a group of life sciences leaders and quantum innovators who are leading the way in quantum applications in the life sciences. Topics included The Quantum State: Where are We Today, Quantum and AI, Redefining Cancer Treatment: Applied Quantum for Precision Oncology, The Biopharma Perspective: Building A Quantum Strategy in Drug Discovery and Development, Investor Outlook and Investor Outlook. Our speakers included: Eric Paley, Secretary of Economic Development, Commonwealth of Massachusetts, Tim Menke, PhD, Co-founder and COO, Atlantic Quantum (acquired by Google), Woody Sherman, PhD, Chief Innovation Officer, PsiThera, Vinit Nijhawan, Managing Director, MassVentures, Bruce Church, PhD, Chief Mathematics Officer & EVP Research & Early Development, Aitia
Hrant Gharibyan, PhD, CEO, BlueQubit, Tyler Fohrman, Early Stage Investor, Glasswing Ventures, Sella Brosh, MD, CEO, NVision, Sanjoy Ray, PhD, Co-founder and CSO, PexMachina, Varun Ramdevan, Global Lead Technology Early Innovation and Partnerships, Johnson & Johnson Innovation, Alexey Galda, PhD, Associate Scientific Director, Quantum Algorithms and Applications, Moderna, Ramani Varanasi, CEO, LIBRIS Innovations, Mark Adams, PhD, Partner, Two Bear Capital
Vinny Beranek, PhD, Partner, Engine Ventures, Kristina Kitko, PhD, Director of Venture Science, Eli Lilly and Company, Stacy Swider, VP Investments, MassVentures, Nicholas Burns, former Ambassador to China; Vice Chair, Cohen Group, Travis Scholten, PhD, Technical Lead, Public Sector, IBM and Larissa Bifano, Partner, DLA Piper.

SALON SERIES
December 4, 2025
40 Thorndike Street
Cambridge MA

From Biopharma Challenge to Quantum Use Case
Long before application and implementation, the first step in applying quantum advantages to drug discovery is to define an optimal use case. During the final program of our 2025 series, Doug Clark, Executive Director, Technology, Analytics and Data Insights, Biogen and Joshua Batkay, Computational Physics and Quantum Computing, BlueQubit, walked through the steps to translate a biopharma challenge into a quantum use case. 

September 10, 2025
Merck Research Laboratories | Cambridge MA
Defining the Tipping Point

This program brought together thought leaders from biopharma, research, computational science, hardware development and investors to define the tipping point for quantum applications in the life sciences. Building on the first program in the series (where we talked about defining the ROI, created an impact framework and presented some compelling use cases), this program took a deeper dive into several use cases while collaborating around defining the tipping point for the quantum applications in the life sciences and how we can work together to make it happen.

June 18, 2025
J&J Innovation Center
Cambridge MA

The topic for this program was “Where is the ROI Today”. we discussed a framework to define the potential impact of quantum computing on the life sciences, shared input on the impact of three vectors: biochemistry, medical research/development of better targets and optimization of processes and suggested probable applications.